Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $585,937.50 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total value of $585,937.50. Following the completion of the transaction, the chief executive officer now owns 307,972 shares in the company, valued at approximately $11,548,950. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, August 21st, Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock. The shares were sold at an average price of $39.76, for a total transaction of $575,366.96.

Vera Therapeutics Price Performance

NASDAQ VERA opened at $37.51 on Monday. The stock’s fifty day moving average price is $37.00 and its 200 day moving average price is $39.20. Vera Therapeutics, Inc. has a 1 year low of $9.24 and a 1 year high of $50.78. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.43 and a quick ratio of 21.43. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -18.30 and a beta of 0.99.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06). As a group, equities research analysts forecast that Vera Therapeutics, Inc. will post -2.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on VERA. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a research report on Friday, September 6th. JPMorgan Chase & Co. raised their price objective on Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Vera Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $51.75.

Institutional Trading of Vera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund increased its stake in shares of Vera Therapeutics by 55.5% in the fourth quarter. New York State Common Retirement Fund now owns 17,491 shares of the company’s stock worth $269,000 after acquiring an additional 6,244 shares during the period. Crestline Management LP raised its stake in shares of Vera Therapeutics by 32.4% during the 4th quarter. Crestline Management LP now owns 60,069 shares of the company’s stock valued at $924,000 after buying an additional 14,689 shares during the last quarter. Rafferty Asset Management LLC lifted its holdings in shares of Vera Therapeutics by 25.2% in the 4th quarter. Rafferty Asset Management LLC now owns 170,758 shares of the company’s stock valued at $2,626,000 after buying an additional 34,381 shares during the period. Schroder Investment Management Group purchased a new stake in shares of Vera Therapeutics in the fourth quarter worth about $17,087,000. Finally, Pale Fire Capital SE purchased a new stake in shares of Vera Therapeutics in the fourth quarter worth about $252,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.